Identification of Novel CAF Target FABP1 and Its Therapeutic Ligand Alitretinoin for Pancreatic Ductal Adenocarcinoma Using Quantitative Proteomics and Molecular Docking
Global Biomedical Frontiers · 04.11.2026 · 1 (2)
DOI: 10.67206/jk1k2r68 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Biomedical Frontiers, online erschienen am 04.11.2026. Verfasst von Xiaoyu Bai.
Abstract (Originalsprache)
Cancer‑associated fibroblasts (CAFs) within the tumor microenvironment are major drivers of chemoresistance in pancreatic ductal adenocarcinoma (PDAC). However, specific molecular targets for CAF‑directed therapy and clinically available repurposed drugs remain scarce. In the present study, quantitative proteomic data comparing CAFs and normal fibroblasts (NFs) derived from our in‑house PDAC dataset were analyzed. Genes significantly upregulated in CAFs and markedly downregulated upon prednisolone exposure were screened. Retinol‑metabolizing enzyme ALDH8A1 was identified, whose catalytic product 9‑cis‑retinoic acid corresponds to the approved drug alitretinoin. Three‑dimensional structures of target protein and candidate ligands were retrieved from the RCSB PDB and PubChem databases. SwissDock‑based molecular‑docking was performed to assess binding affinities between FABP1 and 9‑cis‑retinoic acid, alongside other retinol‑related metabolites and clinically used antitumor agents. Homologous protein FABP5 was included as a control to evaluate subtype‑specificity. The MolModa tool was further applied for multidimensional druggability assessment of all FABP1 binding pockets, followed by replicate‑docking validation. Our docking results revealed that 9‑cis‑retinoic acid bound to FABP1 with a binding free energy of −10.542 kcal/mol, representing substantially higher affinity relative to other ligands and FABP5. Pocket3Box was defined as the optimal binding cavity, with the lowest binding free energy of −9.656 kcal/mol in replicate‑docking assays, confirming robust and subtype‑specific high‑affinity interaction. Subsequent cellular transcriptomic experiments demonstrated that 9‑cis‑retinoic acid potently suppressed activation, pro‑tumorigenic secretion and proliferative phenotypes of pancreatic stellate cells, while globally rewiring cellular lipid metabolic homeostasis. These findings provide direct experimental evidence supporting 9‑cis‑retinoic acid‑mediated inhibition of PDAC CAFs. Collectively, FABP1 binds 9‑cis‑retinoic acid (alitretinoin, an FDA‑approved drug with established clinical safety and pharmacokinetic profiles) with high subtype selectivity and ultra‑high affinity. This target‑drug pairing “FABP1‑alitretinoin” establishes a novel drug‑repurposing strategy for stroma‑targeted intervention in PDAC, which is ready for further in‑vitro and in‑vivo experimental validation.
Zitieren
APA
Bai, X. (2026). Identification of Novel CAF Target FABP1 and Its Therapeutic Ligand Alitretinoin for Pancreatic Ductal Adenocarcinoma Using Quantitative Proteomics and Molecular Docking. Global Biomedical Frontiers, 1(2). https://doi.org/10.67206/jk1k2r68
Vancouver
Bai X. Identification of Novel CAF Target FABP1 and Its Therapeutic Ligand Alitretinoin for Pancreatic Ductal Adenocarcinoma Using Quantitative Proteomics and Molecular Docking. Global Biomedical Frontiers. 2026;1(2). doi:10.67206/jk1k2r68
BibTeX
@article{Bai2026,
author = {Bai, Xiaoyu},
title = {Identification of Novel CAF Target FABP1 and Its Therapeutic Ligand Alitretinoin for Pancreatic Ductal Adenocarcinoma Using Quantitative Proteomics and Molecular Docking},
journal = {Global Biomedical Frontiers},
year = {2026},
volume = {1},
number = {2},
doi = {10.67206/jk1k2r68}
}
EUVIMED